Usercentrics Surpasses €100M ARR ($117M USD) as Market Leader in Data Privacy, Paving the Way for Privacy-Led Marketing
The marketing playbook is being rewritten. AI is accelerating, and consumers want more control than ever. In this new reality, privacy isn’t a constraint - it’s the currency of trust.
Usercentrics today announced it surpassed €100 million in Annual Recurring Revenue (ARR), approximately $117 million USD in late August, to the tune of profitable 45% YoY growth,powered by millions of users. This milestone elevates Usercentrics into the elite “centaur” category - SaaS companies generating over €100 million in recurring revenue annually. With fewer than 200 private companies worldwide at this level, centaur status is increasingly viewed as a more meaningful benchmark than unicorn valuations, which can be inflated by high multiples on lower revenues. The milestone cements Usercentrics’ position as the leader of a new marketing era: Privacy-Led Marketing - trusted by millions of users worldwide and strengthened through strategic partnerships with global technology leaders, including Google, Amazon, and Microsoft.
Privacy Pays Off
With AI accelerating and expectations rising, the connection between privacy and trust has never been more vital and the global landscape is shifting fast: 82% of the world’s population is now covered by some form of data privacy regulation (IAPP, 2025), and people are responding. They vote with their wallets, and trust is now the most valuable currency. According to Cisco’s 2025 Data Privacy Benchmark Study, a staggering 95% of customers won’t buy from organizations that don’t protect their data. That makes privacy not just a compliance checkbox, but a foundational business imperative.
“Privacy is not just an obligation - it’s a strategic growth engine,” said Donna Dror, CEO of Usercentrics. “We're not simply ensuring compliance; we’re architecting a foundation where trust and data privacy catalyze performance.”
A Profitable Global Movement
Usercentrics processes over 7 billion consents each month across 2.3 million websites/apps and is already the global market leader in digital trust. The company continues to scale profitably and is backing its momentum with strong cash reserves and disciplined operations.
A new North American HQ in New York fortifies Usercentrics’ global presence as it accelerates the adoption of Privacy-Led Marketing in U.S. markets.
Innovation with Integrity
Building on the successful launch of its Server-Side Tagging (SST) platform, Usercentrics is evolving its offerings to help brands collect, activate, and measure consented data across websites, mobile apps, IoT devices, and AI interfaces. These innovations are engineered to deliver greater marketer control, richer insights - all while reinforcing performance and trust. Looking ahead, Usercentrics is exploring targeted M&A opportunities to strengthen its product ecosystem while continuing to deliver sustainable profitability.
About Usercentrics
Usercentrics is the global market leader in data privacy solutions, commanding the largest market share and driving profitable growth. Empowering companies worldwide, its solutions help organizations collect, manage, and measure consented user data across websites, apps, and connected platforms, enabling both compliance and Privacy-Led Marketing.
Learn more at usercentrics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251014687594/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom